CL2013002914A1 - Uso de alisporivir en combinación con el estándar de atención: interferón/ribavirina para preparar un medicamento útil en el tratamiento de hepatitis c (hcv), genotipo 1. - Google Patents

Uso de alisporivir en combinación con el estándar de atención: interferón/ribavirina para preparar un medicamento útil en el tratamiento de hepatitis c (hcv), genotipo 1.

Info

Publication number
CL2013002914A1
CL2013002914A1 CL2013002914A CL2013002914A CL2013002914A1 CL 2013002914 A1 CL2013002914 A1 CL 2013002914A1 CL 2013002914 A CL2013002914 A CL 2013002914A CL 2013002914 A CL2013002914 A CL 2013002914A CL 2013002914 A1 CL2013002914 A1 CL 2013002914A1
Authority
CL
Chile
Prior art keywords
alisporivir
ribavirin
hcv
genotype
interferon
Prior art date
Application number
CL2013002914A
Other languages
English (en)
Inventor
Claudio Avila
Rafael Crabbe
Original Assignee
Novartis Ag
Debiopharm Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45937376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013002914(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Debiopharm Int filed Critical Novartis Ag
Publication of CL2013002914A1 publication Critical patent/CL2013002914A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2013002914A 2011-04-13 2013-10-11 Uso de alisporivir en combinación con el estándar de atención: interferón/ribavirina para preparar un medicamento útil en el tratamiento de hepatitis c (hcv), genotipo 1. CL2013002914A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161474946P 2011-04-13 2011-04-13

Publications (1)

Publication Number Publication Date
CL2013002914A1 true CL2013002914A1 (es) 2014-06-27

Family

ID=45937376

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013002914A CL2013002914A1 (es) 2011-04-13 2013-10-11 Uso de alisporivir en combinación con el estándar de atención: interferón/ribavirina para preparar un medicamento útil en el tratamiento de hepatitis c (hcv), genotipo 1.

Country Status (18)

Country Link
US (2) US20150104415A1 (es)
EP (1) EP2696883A1 (es)
JP (1) JP2014510772A (es)
KR (1) KR20140011379A (es)
CN (1) CN103648516A (es)
AR (1) AR085988A1 (es)
AU (2) AU2012241859A1 (es)
BR (1) BR112013025934A2 (es)
CA (1) CA2832829A1 (es)
CL (1) CL2013002914A1 (es)
IL (1) IL228725A0 (es)
MA (1) MA35029B1 (es)
MX (1) MX2013011941A (es)
RU (1) RU2013150344A (es)
SG (2) SG10201602184TA (es)
TN (1) TN2013000397A1 (es)
TW (1) TW201247217A (es)
WO (1) WO2012140082A1 (es)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
ATE214940T1 (de) 1993-11-10 2002-04-15 Enzon Inc Verbesserte interferon-polymerkonjugate
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6924270B2 (en) 2000-04-20 2005-08-02 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
NZ554412A (en) * 2004-10-01 2011-01-28 Debiopharm Sa Use of [D-MeAla]3-[EtVal]4-cyclosporin for the treatment of hepatitis C infection and pharmaceutical composition comprising said [D-MeAla]3-[EtVal]4-cyclosporin
KR20070087624A (ko) 2004-12-23 2007-08-28 노파르티스 아게 Ｈｃｖ 치료용 조성물
WO2008052722A2 (en) 2006-11-02 2008-05-08 Heidelberg Pharma Ag Use of ribavirin-conjugates as an anti-viral drug

Also Published As

Publication number Publication date
BR112013025934A2 (pt) 2016-09-06
WO2012140082A1 (en) 2012-10-18
US20160235808A1 (en) 2016-08-18
MX2013011941A (es) 2014-05-28
TW201247217A (en) 2012-12-01
US20150104415A1 (en) 2015-04-16
NZ615539A (en) 2016-01-29
RU2013150344A (ru) 2015-05-20
KR20140011379A (ko) 2014-01-28
TN2013000397A1 (en) 2015-01-20
AU2012241859A1 (en) 2013-10-10
AR085988A1 (es) 2013-11-13
SG193908A1 (en) 2013-11-29
IL228725A0 (en) 2013-12-31
CA2832829A1 (en) 2012-10-18
MA35029B1 (fr) 2014-04-03
EP2696883A1 (en) 2014-02-19
SG10201602184TA (en) 2016-04-28
JP2014510772A (ja) 2014-05-01
CN103648516A (zh) 2014-03-19
AU2016200061A1 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
CL2015001702A1 (es) Compuestos triciclicos antivirales; composicion farmaceutica; y uso en el tratamiento de la hepatitis c.
CL2015001699A1 (es) Compuestos derivados de nucleosidos, nucleotidos y analogos de los mismos; composicion farmaceutica; y su uso para preparar un medicamento util en el tratamiento de la hepatitis c.
CL2013001428A1 (es) Compuesto que inhibe la actividad del virus de la hepatitis c (hcv); composición farmacéutica que comprende el compuesto; método de tratamiento de hepatitis c.
CL2013002939A1 (es) Compuestos derivados de nucleosidos 2´-sustituidos , inhibidores ns5a; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
CL2016001509A1 (es) Formas cristalinas de los análogos de sofosbuvir antivirales
CL2014000428A1 (es) Metodo para el tratamiento de hepatitis c (hcv) que comprende administrar un compuesto de formula (i), (ii) o (iii) en combinacion con uno o mas agentes terapeuticos; composicion farmaceutica.
SG2014011647A (en) Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon.
CO6950473A2 (es) Novedosos derivados de purina y su uso en el tratamiento de enfermedades
CL2015000784A1 (es) Compuestos derivados de acilaminopirimidina, inductores de interferon; composicion farmaceutica que los comprende; su uso en el tratamiento de infecciones viricas, trastornos inmunitarios, cancer y otras enfermedades.
DK2528930T3 (da) 4'-azido-nukleosider som anti-hcv-forbindelser
PL2739615T3 (pl) Fenylo-3-aza-bicyklo[3.1.0]heks-3-ylo-metanony i ich zastosowanie jako leki
MX2015017953A (es) Metodos para tratar el virus de hepatitis c.
CL2013002914A1 (es) Uso de alisporivir en combinación con el estándar de atención: interferón/ribavirina para preparar un medicamento útil en el tratamiento de hepatitis c (hcv), genotipo 1.
CL2007001003A1 (es) Compuestos derivados de amidas; y uso en el tratamiento de un trastorno asociado con el virus de hepatitis c.
CL2013000210A1 (es) Compuestos derivados de tiofeno 2,3,5 trisustituidos; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento de un trastorno o enfermedad en un sujeto causado o asociado con una infeccion por vhc, tales como cirrosis hepatica, carcinoma hepatocelular, entre otras.
Wilkinson et al. Negotiated boundaries: The role of social scientists in public engagement with science and technology (PEST)
CL2012002092A1 (es) Composicion farmaceutica que comprende vx-222 y vx-950; donde vx-950 mejora la farmacocinetica de vx -222; uso en el tratamiento de la hepatitis c.
石文敏 A Letter to John
邹中娥 Travel with Lily
CO6801760A2 (es) Uso de las sales de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio en el tratamiento de enfermedad cardiovascular
CL2013000181A1 (es) Conjugado estable de interferon alfa pegilado; composicion farmaceutica que comprende dicho conjugado; uso de conjugado para preparar medicamento antiviral, antiproliferativo e inmunomodulatorio.
TH133140S (th) เก้าอี้
TH133099B (th) อุปกรณ์รองนั่งสำหรับขับถ่าย
RU2011133053A (ru) Телескопическая ложка
ES1068086Y (es) Mesa de trabajo modular, para el montaje de faldones en encimeras y analogos